| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000017836 |
| Receipt No. | R000020666 |
| Official scientific title of the study | Molecular and therapeutic apploaches of autosomal recessive familial Alzheimer's disease using APPE693dlta-iPS cells. |
| Date of disclosure of the study information | 2015/06/08 |
| Last modified on | 2016/05/19 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Molecular and therapeutic apploaches of autosomal recessive familial Alzheimer's disease using APPE693dlta-iPS cells. | |
| Title of the study (Brief title) | Analysis of disease-causing mutant APP (E693delta) iPS cells | |
| Region |
|
|
| Condition | ||
| Condition | Familial Alzheimer's disease(APP E693delta). | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | Establishment of the iPS cells from a patient with familial Alzheimer's disease(APP E693delta). |
| Basic objectives2 | Others |
| Basic objectives -Others | Screening of small-molecule inhibitors preventing familial Alzheimer's disease(APP E693delta). |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Establishment of the iPS cells from a patient with familial Alzheimer's disease(APP E693delta). |
| Key secondary outcomes | Screening of small-molecule inhibitors preventing familial Alzheimer's disease(APP E693delta). |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Introduction of Yamanaka's factor into patient-derived somatic cells. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Patients havoring APP-E693delta | |||
| Key exclusion criteria | none | |||
| Target sample size | 1 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshihide Sunada |
| Organization | Kawasaki Medical School
|
| Division name | Neurology |
| Address | 577 Matsushima, Kurashiki, Okayama |
| TEL | 0864621111 |
| ysunada@med.kawasaki-m.ac.jp | |
| Public contact | |
| Name of contact person | Yoshihide Sunada |
| Organization | Kawasaki Medical School |
| Division name | Neurology |
| Address | 577 Matsushima, Kurashiki, Okayama |
| TEL | 0864621111 |
| Homepage URL | |
| ysunada@med.kawasaki-m.ac.jp | |
| Sponsor | |
| Institute | Kawasaki Medical School |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Kawasaki Medical School |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020666 |